Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report

被引：0
作者：
So-Yeon Jeon
Na-Ri Lee
Chang-Yeol Yim
机构：
[1] Chonbuk National University Medical School,Department of Internal Medicine
[2] Research Institute of Clinical Medicine of Chonbuk National University – Biomedical Research Institute of Chonbuk National University Hospital,undefined
来源：
BMC Nephrology | / 20卷
关键词：
Pazopanib; Nephrotic syndrome; Metastatic renal cell carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 40 条
[1]  
Sonpavde G(2007)Pazopanib: a novel multitargeted tyrosine kinase inhibitor Curr Oncol Rep 9 115-119
[2]  
Hutson TE(2013)A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update Eur J Cancer 49 1287-1296
[3]  
Sternberg CN(2016)Proteinuria with first-line therapy of metastatic renal cell cancer J Oncol Pham Pract 22 235-241
[4]  
Hawkins RE(1986)Adult-onset minimal change nephrotic syndrome: a long-term follow-up Kidney Int 29 1215-1223
[5]  
Wagstaff J(2010)VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management Eur J Cancer 46 439-448
[6]  
Salman P(2007)Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension Am J Kidney Dis 50 203-218
[7]  
Mardiak J(2015)Inhibition of the VEGF signalling pathway and glomerular disorders Nephrol Dial Transplant 30 1449-1455
[8]  
Barrios CH(2015)Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a southern China urology Cancer consortium trial Eur J Cancer 51 595-603
[9]  
Land JD(2017)Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) J Nephrol 30 171-180
[10]  
Chen AH(undefined)undefined undefined undefined undefined-undefined
1234